E Fund Management’s Sana Biotechnology SANA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$96.8K Sell
27,740
-16,706
-38% -$53.8K ﹤0.01% 475
2026
Q1
$128K Buy
+44,446
New +$175K ﹤0.01% 468
2025
Q2
Sell
-18,236
Closed -$30.6K 422
2025
Q1
$30.6K Sell
18,236
-3,966
-18% -$11.1K ﹤0.01% 396
2024
Q4
$36.2K Buy
22,202
+1,612
+8% +$4.81K ﹤0.01% 389
2024
Q3
$85.7K Sell
20,590
-85
-0.4% -$447 ﹤0.01% 343
2024
Q2
$113K Sell
20,675
-2,686
-11% -$21.4K 0.01% 303
2024
Q1
$234K Hold
23,361
0.01% 316
2023
Q4
$95.3K Buy
23,361
+6,673
+40% +$24.6K 0.01% 302
2023
Q3
$65K Sell
16,688
-1,366
-8% -$7.34K ﹤0.01% 289
2023
Q2
$108K Sell
18,054
-5,126
-22% -$29.5K 0.01% 300
2023
Q1
$76K Sell
23,180
-3,644
-14% -$14.6K 0.01% 327
2022
Q4
$106K Sell
26,824
-2,671
-9% -$13.1K 0.01% 327
2022
Q3
$177K Sell
29,495
-12,957
-31% -$93.5K 0.02% 313
2022
Q2
$273K Buy
42,452
+18,124
+74% +$115K 0.02% 249
2022
Q1
$201K Buy
+24,328
New +$197K 0.01% 297

Other funds holding SANA

E Fund Management's SANA Position: Q2 2026 in Review

E Fund Management reduced its Sana Biotechnology (SANA) stake by 38% in Q2 2026, selling an estimated $53.8K and leaving 27,740 shares worth $96.8K. The position accounts for ﹤0.01% of the portfolio, ranked #475.

E Fund Management first reported a position in SANA in Q1 2022 and has held it in 15 quarters since. The position peaked at $273K in Q2 2022. 212 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • E Fund Management held 27,740 shares of Sana Biotechnology worth $96.8K as of Q2 2026.
  • E Fund Management sold 16,706 Sana Biotechnology shares in Q2 2026, an estimated $53.8K.
  • Sana Biotechnology made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #475 holding.
  • E Fund Management first reported a position in Sana Biotechnology in Q1 2022 and has held it in 15 quarters since.
  • E Fund Management's Sana Biotechnology position peaked at $273K in Q2 2022.
  • 212 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.